isobutyrylshikonin: from root of Lithospermum erythrorhizon; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Lithospermum | genus | A plant genus of the family BORAGINACEAE. Members contain lithospermans and lithospermic acid.[MeSH] | Boraginaceae | The Borage plant family is in the class Magnoliopsida, subclass Asteridae, order Lamiales. It is characterized by hairy foliage, usually alternate and simple; flowers are funnel-shaped or tubular. Some of the species contain PYRROLIZIDINE ALKALOIDS.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 479500 |
| SCHEMBL ID | 3298557 |
| MeSH ID | M000608176 |
| Synonym |
|---|
| [(1r)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] 2-methylpropanoate |
| isobutylshikonin |
| C17414 |
| isobutyrylshikonin |
| SCHEMBL3298557 |
| 52438-12-7 |
| AC-35024 |
| FT-0770577 |
| Q27155026 |
| MS-25632 |
| DTXSID901316067 |
| CCA43812 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In this study, we investigated erlotinib in combination with shikonin and 14 shikonin derivatives in parental U87MG and transfected U87MG." | ( Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib. Bauer, R; Efferth, T; Kretschmer, N; Zhao, Q, 2015) | 0.42 |
| Class | Description |
|---|---|
| hydroxy-1,4-naphthoquinone | Any member of the class of 1,4-naphthoquinones in which the naphthoquinone moiety is substituted by at least one hydroxy group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||